Lamorde, MohammedByakika-Kibwika, PaulineMayito, JonathanNabukeera, LillianRyan, MairinHanpithakpong, WaruneeLefe`vree, GilbertBackf, David J.Khoof, Saye H.Merry, Concepta2022-01-122022-01-122013Lamorde, M., Byakika-Kibwika, P., Mayito, J., Nabukeera, L., Ryan, M., Hanpithakpong, W., ... & Merry, C. (2013). Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. Aids , 27 (6), 961-965. DOI:10.1097/QAD.0b013e32835cae3b0269-937010.1097/QAD.0b013e32835cae3bhttps://nru.uncst.go.ug/xmlui/handle/123456789/1224Malaria and tuberculosis (TB) are co-endemic in many parts of the developing world. Although malaria transmission may occur throughout the duration of TB treatment, drug data between antimalarial drugs and anti- TB drugs are limited [1]. The WHO recommends artemisinin combination therapies (ACTs) for uncomplicated malaria caused by Plasmodium falciparum, whereas for TB treatment, the WHO recommends rifampicinbased therapy [2,3]. However, no data exist on drug interactions between ACTs and rifampicin-based TB treatment.enArtemether-lumefantrine combinationDrug interactionsRifampicinArticle